The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
@article{Pitt1999TheEO,
title={The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.},
author={Bertram Pitt and Faiez Zannad and Willem J. Remme and Rosemary Cody and Alain Castaigne and Alberto Luis Rodrigues Perez and Jolie Palensky and Janet Wittes},
journal={The New England journal of medicine},
year={1999},
volume={341 10},
pages={
709-17
}
}BACKGROUND AND METHODS
Aldosterone is important in the pathophysiology of heart failure. In a doubleblind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was… CONTINUE READING
Paper Mentions
INTERVENTIONAL CLINICAL TRIAL
The purpose of this study is to determine if patients who receive an early radiofrequency
ablation will have fewer hospitalizations, unplanned office visits, and emergency room visits… Expand
| Conditions | Heart Failure With Preserved Ejection Fraction |
|---|---|
| Intervention | Procedure |
INTERVENTIONAL CLINICAL TRIAL
Hypertrophic Cardiomyopathy (HCM) is the most common hereditary heart disease with high
mortality. Heart failure is the most common complication (about 50% incidence) in these… Expand
| Conditions | Fibrosis, Hypertrophic Cardiomyopathy |
|---|---|
| Intervention | Drug |
BLOG POST
INTERVENTIONAL CLINICAL TRIAL
In stage 3 chronic kidney disease (CKD) the risk of death due to cardiovascular causes is
high and greatly exceeds the risk of progression to end stage renal failure. This high… Expand
| Conditions | Cardio-Renal Syndrome, Renal Insufficiency, Chronic |
|---|---|
| Intervention | Drug |
Citations
Publications citing this paper.
SHOWING 1-10 OF 2,640 CITATIONS, ESTIMATED 43% COVERAGE
FILTER CITATIONS BY YEAR
CITATION STATISTICS
79 Highly Influenced Citations
Averaged 196 Citations per year from 2018 through 2020
References
Publications referenced by this paper.
SHOWING 1-10 OF 38 REFERENCES
Captopril in heart failure. A double blind controlled trial.
VIEW 2 EXCERPTS